AddLife AB Earnings Call: Margins Up, FX Weighs

AddLife AB Class B (($SE:ALIF.B)) has held its Q4 earnings call. Read on for the main highlights of the call.

AddLife AB Earnings Call Highlights Steady Margin Gains Amid Currency and Market Headwinds

Management at AddLife AB Class B struck a confident but measured tone during the latest earnings call, underscoring a clear trend of margin improvement, strong cash flow and rapid deleveraging, even as currency headwinds, softer demand in certain markets and operational disruptions weighed on reported growth. The company framed 2025 as a year of disciplined execution on profitability and portfolio quality, setting the stage for a more active acquisition phase beyond the near term.

Improved Profitability and Margins

AddLife delivered another quarter of incremental margin gains, confirming that its profit-improvement measures are taking hold. Adjusted EBITA margin edged up to 12.4% in the quarter, versus 12.3% a year earlier, while full-year EBITA margin improved to about 12.1%, up from 11.3% the prior year and 10.5% in 2023. Both divisions contributed: Labtech posted a robust Q4 margin of 14.1% with a full-year level around 12.5%, and Medtech lifted its Q4 margin to 12.0% (from 11.6%), with a full-year margin around 12.4%. For investors, the consistent year-on-year lift in profitability signals that structural initiatives rather than one-offs are driving the earnings trajectory.

Strong Cash Generation and Working Capital Performance

Cash metrics were a standout, reinforcing the quality of AddLife’s earnings. Operating cash flow came in at almost SEK 900 million for the quarter and SEK 1.4 billion for the full year, supported by disciplined working-capital management. Working capital released SEK 426 million in the quarter, helping inventory-to-sales improve to 16%, down from 17% in 2024. Cash conversion was a high 111% for the year, or 98% excluding the impact of business disposals, indicating that the company is turning profits into cash efficiently. This strong cash profile not only underpins deleveraging but also offers firepower for future M&A.

Debt Reduction and Balance Sheet Strengthening

The company used its cash generation to materially strengthen the balance sheet, reducing net debt by almost SEK 900 million over 2025, including roughly SEK 800 million in the fourth quarter alone. Net debt-to-EBITDA ended at 2.2, comfortably below the company’s ceiling of 3, while net debt-to-adjusted EBITA was 2.5. This rapid deleveraging gives AddLife more flexibility to pursue acquisitions and cushions the business against macro volatility. For shareholders, the lower leverage increases financial resilience while still leaving room for disciplined growth investments.

Organic and Acquisition-Fueled Growth in 2025

Growth in 2025 was driven predominantly by the underlying business, with organic sales up about 10% for the full year and acquired growth contributing roughly 2%. Total EBITA growth reached around 8% for the year. In the latest quarter, currency-adjusted sales rose about 2%, while adjusted EBITA grew around 5%, underscoring operating leverage despite a tougher environment. The mix of high single- to low double-digit organic growth and moderate M&A contribution suggests that AddLife has room to re-accelerate total growth once external pressures ease and deal activity increases.

Portfolio and Margin Improvement Initiatives Paying Off

Management detailed several initiatives underpinning the margin uplift, focusing heavily on portfolio quality rather than volume at any price. Gross margins improved, driven by disciplined price management, a shift toward higher-margin products and new tenders, and a deliberate pruning of low-margin SKUs. An increasing share of own-branded products also supported profitability. These actions are gradually reweighting the business toward more attractive revenue streams, which should enhance earnings resilience even in slower demand conditions.

Active M&A Pipeline and Selected Additions

Despite a more cautious acquisition tempo, AddLife continued to selectively add to its portfolio. In December, the company acquired Pharmacold, extending its capabilities in medical refrigeration, and Opitek, which strengthens its position in patient positioning solutions. Management highlighted a healthy pipeline of potential deals, typically in the EUR 10–30 million turnover range, and reiterated a disciplined stance on valuation. With leverage now below target levels, the company is well-positioned to step up M&A when conditions and pricing align, aiming for a more balanced contribution between organic and acquired growth over time.

Significant Currency Headwinds

Currency movements materially dampened reported results, masking the underlying operational progress. While currency-adjusted sales grew modestly, reported revenue in the quarter declined by about 5% due to FX effects, and management cited around a 7% negative impact on EBITA. Including currencies, some segments even showed negative reported sales growth, with overall sales including FX down about 3% in the quarter. For investors, this means the underlying business is performing better than the headline numbers suggest, though FX remains an uncontrollable swing factor for near-term results.

Softness in Specific End Markets and Product Areas

Not all end markets moved in AddLife’s favor. Labtech saw slightly lower instrument sales compared with an exceptionally strong Q4 in 2024, with currency-adjusted revenues down about 3% in the quarter. Management noted hesitancy in academic research spending and some caution within pharma-related segments, particularly affecting high-ticket instrument demand. This selective softness serves as a reminder that AddLife’s growth profile is partly tied to research and healthcare investment cycles, which can pause even when long-term demand fundamentals remain intact.

UK and Spain Operational Disruptions

Operational challenges in the UK and Spain created additional short-term pressure. Strikes and a flu wave led to lost surgical days and weaker elective procedure volumes in December, temporarily reducing capital and procedure-linked sales. In parallel, AddLife completed the handover of a UK endoscopy business to its supplier, a move that came with a SEK 158 million consideration but also removed a stream of recurring revenue from that line. While management framed these impacts as largely one-off and manageable, they nonetheless weighed on the quarter’s reported performance.

Sub-Par Margins in Certain Subsidiaries

Within the group, not all units are yet meeting profitability ambitions. The AddVision operations in the UK and Germany were called out as remaining in the mid-single-digit margin range—better than before but still below the group average. Management signaled that further measures are needed to lift these operations toward targeted profitability levels. Investors should expect ongoing restructuring and efficiency work in these subsidiaries, with the potential for future margin upside if the turnaround efforts succeed.

Revenue Impact from Divestments and Portfolio Shaping

AddLife’s portfolio cleanup has also had a tangible, though deliberate, impact on reported sales. The divestment and handover of the UK endoscopy business not only generated cash proceeds but reduced recurring revenue, with management referring to around SEK 140 million in sales coming out of the run rate. Additional tail-cutting and discontinuation of lower-value products contributed roughly a 1% reduction in sales versus the prior base. The company expects these trimmed revenues to be gradually replaced over time with higher-quality business rather than immediately offset, prioritizing profitability over sheer top-line volume.

Geographic Exposure Weaknesses

Geographically, some pockets of weakness persisted, particularly outside AddLife’s core Nordic and European markets. Sales in the “rest of world” category—including China, Australia and certain U.S. exposures—were lower, with specific group companies that serve the U.S. research market facing softer demand. While management stressed that these areas are not large enough to drive group-level performance on their own, they represent headwinds for the affected units and a reminder of the company’s exposure to global research and healthcare spending cycles.

Forward-Looking Guidance and Strategic Priorities

Looking ahead into 2026, management reiterated its commitment to continuing the profit-improvement agenda, aiming for further EBITA margin expansion from the current group level of 12.1% (Q4 adjusted EBITA at 12.4%; Labtech Q4 at 14.1% and Medtech Q4 at 12.0%). The company plans to balance organic and acquisition-driven growth over time, gradually moving back toward an approximate 50/50 contribution as M&A activity ramps up from its current, more selective pace. A strengthened balance sheet—with net debt/EBITDA at 2.2 and net debt/adjusted EBITA at 2.5—supports this strategy. Cash generation and working-capital efficiency remain central, with management targeting a sustainable cash conversion level around the mid-90s percent and maintaining its long-term objectives of 15% year-on-year profit improvement and profit-to-working-capital above 45%, compared with 62% in 2025. Overall, the guidance points to continued margin focus, disciplined portfolio management and a readiness to accelerate deal-making when the timing and valuations are right.

In summary, AddLife’s earnings call painted a picture of a company that is trading some short-term growth and revenue stability for a sturdier, higher-margin business model. FX headwinds, localized market softness and temporary operational issues clouded reported numbers, yet underlying margins, cash flow and leverage trends all moved in the right direction. For investors following the stock, the key takeaways are steady execution on profitability, a stronger financial base to support future acquisitions and management’s clear intent to prioritize quality of earnings over headline sales growth.